A five-year secondary analysis of the phase 2 PHERGain trial supports a PET-guided adaptive strategy that reduces chemotherapy in HER2-positive early breast cancer, while exploratory circulating tumor DNA findings may shape future treatment decisions.
PET-guided treatment de-escalation keeps HER2-positive breast cancer outcomes strong at five years
A five-year secondary analysis of the phase 2 PHERGain trial supports a PET-guided adaptive strategy that reduces chemotherapy in HER2-positive early breast cancer, while exploratory circulating tumor DNA findings may shape future treatment decisions.
Jenny Mealing · CC BY 2.0 · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.